Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
Ultan McDermott(AstraZeneca (United Kingdom)), Jeffrey Settleman(Enzo Life Sciences (United States)), Georgiana Kuhlmann(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), A. John Iafrate(Massachusetts General Hospital), Lori Dowell(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), James G. Christensen, Patricia Greninger(Harvard University), Hwan Geun Choi(Harvard University), Wenjun Zhou(Shanghai Innovative Research Center of Traditional Chinese Medicine), Lindsey E. Ulkus(Harvard University), Shannon L. Smith(Harvard University), Toshi Shioda(Center for Cancer Research), Marie Classon(Pfizer (United States)), Nathanael S. Gray(Stanford University)
Cited by 403
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
|Endocrine Reviews|2012|3.1k